Spotlight Series on Hepatitis C

International News

Merck's Hepatitis C Drug Wins UK Cost Endorsement

March 12, 2012

The National Institute for Health and Clinical Excellence (NICE) on Friday recommended Merck & Co.'s new hepatitis C drug Victrelis (boceprevir) for use in Britain's state health service. Although it often shuns expensive new treatments on cost grounds, NICE noted that the significant improvements seen with Victrelis make it a cost-effective option. Victrelis costs £30,800 (US $48,109) for a 44-week regimen; it is designed to be administered with peginterferon-alfa and ribavirin, which add £11,000 (US $17,178) to the total. The draft guidelines are open for consultation before final approval.

Back to other news for March 2012

Adapted from:

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.